Recombinant Zebrafish ALDH3A2A

• Cat.No.: ALDH3A2A-11926Z
• Product Overview: Recombinant Zebrafish ALDH3A2A full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: aldh3a2a aldehyde dehydrogenase 3 family, member A2a [ Danio rerio (zebrafish) ]
• Official Symbol: ALDH3A2A
• Gene ID: 323653
• mRNA Refseq: NM_212649
• Protein Refseq: NP_997814
• UniProt ID: Q90ZZ8

Reviews

01/15/2021

The ALDH3A2A Protein is of exceptional quality and is precisely tailored to meet my experimental requirements.

08/15/2020

What sets this protein apart is the outstanding technical support provided by the manufacturer.

09/07/2017

Their prompt and knowledgeable assistance has been instrumental in overcoming hurdles and has significantly contributed to the success of my research.

07/09/2016

The ALDH3A2A Protein exhibits remarkable stability and functionality, making it an optimal choice for a wide range of applications in various fields.

Q&As

Are there any known inhibitors or activators of ALDH3A2?

The specific inhibitors or activators of ALDH3A2 have not been extensively characterized. However, it is known that ALDH3A2 activity can be influenced by its substrate availability and cellular environment. For example, increased levels of long-chain fatty aldehydes, the substrates of ALDH3A2, may stimulate its activity. On the other hand, conditions that decrease substrate availability or impair the function of ALDH3A2 may inhibit its activity. Further research is needed to identify pharmacological inhibitors or activators that can modulate ALDH3A2 function.

Are there any ongoing clinical trials targeting ALDH3A2?

As of my knowledge cutoff date, I do not have access to real-time information about ongoing clinical trials. To find the most up-to-date and accurate information about clinical trials targeting ALDH3A2, it is recommended to search clinical trial databases like ClinicalTrials.gov or consult with medical professionals or researchers specializing in the field.

Are there any known interactions or associations of ALDH3A2 with other proteins or molecules?

The interactions and associations of ALDH3A2 with other proteins or molecules are not extensively studied. However, ALDH3A2 has been reported to associate with protein kinase C delta (PKCδ) and protein kinase C zeta (PKCζ) in keratinocytes, suggesting a potential involvement of these proteins in ALDH3A2 regulation or function.

What are the effects of mutations in the ALDH3A2 gene?

Mutations in the ALDH3A2 gene lead to the development of Sjögren-Larsson syndrome (SLS), which is characterized by a triad of symptoms: ichthyosis (dry, scaly skin), intellectual disability, and spastic diplegia or tetraplegia (spasticity in the limbs). These mutations disrupt the function of the ALDH3A2 protein, impairing its ability to efficiently metabolize long-chain fatty aldehydes. The accumulation of these aldehydes in the body results in the characteristic symptoms associated with SLS.

Is ALDH3A2 involved in any other biological processes or pathways?

While the primary function of ALDH3A2 is the oxidation of lipophilic aldehydes, it may also have additional roles in cellular processes. For example, ALDH3A2 has been implicated in the protection of cells against oxidative stress by reducing the levels of lipid peroxidation products. It may also play a role in the metabolism of retinoids, as suggested by its association with the retinoic acid signaling pathway. However, further research is needed to fully understand the involvement of ALDH3A2 in these processes and pathways.

Are there any known regulatory mechanisms that control the expression or activity of ALDH3A2?

The regulation of ALDH3A2 expression and activity is not fully understood. However, certain transcription factors and signaling pathways have been implicated in its regulation.

Is ALDH3A2 tissue-specific in its expression?

Yes, ALDH3A2 exhibits tissue-specific expression patterns. It is highly expressed in tissues rich in lipid metabolism, such as the skin, liver, and adipose tissue. Within the skin, ALDH3A2 is primarily expressed in the sebaceous glands. The tissue-specific expression of ALDH3A2 suggests its important role in lipid metabolism and protection against toxic aldehydes in these tissues.

Are there any known diseases or disorders associated with dysregulation of ALDH3A2?

Yes, mutations in the ALDH3A2 gene are associated with Sjögren-Larsson syndrome (SLS), a rare autosomal recessive disorder. SLS is characterized by a triad of symptoms: ichthyosis (dry, scaly skin), intellectual disability, and spastic diplegia or tetraplegia (spasticity in the limbs). These symptoms result from the accumulation of long-chain fatty aldehydes due to impaired ALDH3A2 function. SLS is a chronic disorder that affects multiple systems, including the skin, central nervous system, and musculoskeletal system.

What are the potential therapeutic implications of targeting ALDH3A2?

As Sjögren-Larsson syndrome (SLS) is caused by mutations in the ALDH3A2 gene, therapeutic strategies targeting ALDH3A2 could potentially be beneficial for treating this disorder. Currently, there are no specific treatments for SLS, and management focuses on alleviating the symptoms. However, gene therapy approaches, such as gene replacement or gene editing techniques, may hold promise for correcting the underlying genetic defect in ALDH3A2.

In which tissues or organs is ALDH3A2 expressed?

ALDH3A2 is expressed in various tissues and organs throughout the body. It is primarily found in the skin where it participates in lipid metabolism and detoxification of aldehydes produced during cellular processes. ALDH3A2 expression has also been detected in other tissues such as the liver, brain, kidney, lung, and eye, indicating its involvement in general aldehyde detoxification and lipid metabolism in these organs as well.

Does ALDH3A2 have any known interacting proteins?

The specific interacting partners of ALDH3A2 have not been extensively characterized. As of now, there are no well-established protein-protein interactions reported for ALDH3A2 in public protein interaction databases. Further research is needed to identify and characterize potential interacting proteins that may be involved in modulating the activity of ALDH3A2 or its involvement in various cellular processes.